PTGS2, prostaglandin-endoperoxide synthase 2, 5743

N. diseases: 1234; N. variants: 27
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE Artesunate markedly ameliorated aspirin induced gastric injury in rats by targeting oxidative stress and COX-2 dependent as well as COX-2 independent proinflammatory signaling pathways and could have a therapeutic potential in gastric ulcer disease. 29397336 2018
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE Taken together, the activation of AMPK by rebamipide may be a molecular mechanism that contributes to induction of COX-2, probably resulting in protection against gastric ulcers. 28011266 2017
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE Current study was designed to understand the gastric ulcer healing mechanism of rhamnogalacturonan-I type pectic polysaccharide of black cumin (BCPP) utilizing acetic acid induced gastric ulcers in rats.BCPP fed groups at 200mg/kg b.w. for 10days showed up to 85% healing of gastric ulcers with modulation of key molecular events involved in ulcer healing process such as increase in gastric mucin content, cyclooxygenase-2 (Cox-2) and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). 28322956 2017
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE Recent studies suggest that cyclooxygenase 2 (COX-2) inhibitors may enhance the toxic effects of anticancer drugs on tumor cells, including oral squamous cell carcinoma (OSCC), but its long-term use can cause side effects such as stomach ulcers and myocardial infarction. 28342204 2017
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease CTD_human Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice. 19066340 2009
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease RGD These results confirmed the importance of COX-2/PGE2 in the healing mechanism of gastric ulcers and further suggested that the healing-promoting action of PGE2 is mediated by the activation of EP4 receptors and is associated with VEGF expression. 17673547 2007
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 AlteredExpression disease LHGDN We conclude that both COX-1 and COX-2 expression in the gastric mucosa are increased in the setting of gastritis and gastric ulceration. 15720413 2005
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 AlteredExpression disease BEFREE We constructed a prospective cohort study to evaluate how these two factors influence the expression of COX-2 mRNA in gastric antral, corpus mucosa, and gastric ulcer. 15599211 2005
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease LHGDN VEGF and COX-2 expression in surgical resections of human gastric ulcer tissue was examined immunohistochemically. 15246970 2004
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease CTD_human Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats. 12481160 2002
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 AlteredExpression disease BEFREE Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. 11519793 2001
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 AlteredExpression disease BEFREE Both COX-1 and COX-2 are up-regulated in human gastric ulcers. 11136275 2001
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease CTD_human In this study, Wistar rats with gastric ulcers produced by serosal application of acetic acid (ulcer area 28 mm(2)) received daily treatment either with: (1) vehicle (saline); (2) NS-398 (10 mg/kg-d i.g.) and Vioxx (5 mg/kg-d i.g.), both, highly specific COX-2 inhibitors; (3) meloxicam (5 mg/kg-d i.g.), a preferential inhibitor of COX-2; (4) resveratrol (10 mg/kg-d i.g.), a specific COX-1 inhibitor; (5) indomethacin (5 mg/kg-d i.g); and (6) aspirin (ASA; 50 mg/kg-d i.g.), non-selective inhibitors of both COX-1 and COX-2. 11376495 2001
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE Most were reported to be free of adverse gastrointestinal effects, but it should be noted that in the healing process of gastric ulcers and in sodium-restricted states, adverse effects of selective COX-2 inhibitors could be expected. 11028754 2000
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease BEFREE In the following article, the phenotypes of the two Ptgs (genes coding for COX-1 and COX-2) knockouts are summarized, and recent studies to investigate the effects of COX deficiency on cancer susceptibility, inflammatory response, gastric ulceration, and female reproductive processes are discussed. 10487525 1999
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease CTD_human Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. 10594344 1999
CUI: C0038358
Disease: Gastric ulcer
Gastric ulcer
0.600 Biomarker disease CTD_human Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. 9024292 1997